ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,76
0,00%
Bitcoin
66 986,36
-0,14%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Pharvaris NV (PHVS)

  7. Pharvaris NV (PHVS) Actualités

PHVS

Pharvaris NV (PHVS)

Pharvaris NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PHVS
DateHeureSourceTitreSymboleSociété
13/05/202412h50GlobeNewswire Inc.Pharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
08/05/202422h11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
08/05/202422h10GlobeNewswire Inc.Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
10/04/202422h10GlobeNewswire Inc.Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
10/04/202422h08GlobeNewswire Inc.Pharvaris Appoints David Nassif, J.D., as Chief Financial OfficerNASDAQ:PHVSPharvaris NV
04/04/202412h50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceNASDAQ:PHVSPharvaris NV
18/03/202411h50GlobeNewswire Inc.Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesNASDAQ:PHVSPharvaris NV
11/03/202418h51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
06/03/202422h40Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PHVSPharvaris NV
06/03/202412h50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
05/03/202412h50GlobeNewswire Inc.Pharvaris to Participate in the Leerink Global Biopharma Conference 2024NASDAQ:PHVSPharvaris NV
22/02/202412h50GlobeNewswire Inc.Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingNASDAQ:PHVSPharvaris NV
16/02/202412h50GlobeNewswire Inc.Pharvaris Announces Extraordinary Meeting of ShareholdersNASDAQ:PHVSPharvaris NV
26/01/202412h50GlobeNewswire Inc.Pharvaris to Present at the WSAAI Annual Meeting 2024NASDAQ:PHVSPharvaris NV
22/01/202413h35Dow Jones NewsPharvaris Says FDA Lifted Clinical Hold on Application for DeucrictibantNASDAQ:PHVSPharvaris NV
22/01/202412h50GlobeNewswire Inc.Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
05/01/202412h50GlobeNewswire Inc.Pharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesNASDAQ:PHVSPharvaris NV
09/12/202300h00GlobeNewswire Inc.Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023NASDAQ:PHVSPharvaris NV
07/12/202322h17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHVSPharvaris NV
06/12/202313h08Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PHVSPharvaris NV
06/12/202313h02GlobeNewswire Inc.Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded WarrantsNASDAQ:PHVSPharvaris NV
06/12/202312h50GlobeNewswire Inc.Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
30/11/202312h50GlobeNewswire Inc.Pharvaris to Present at the GA²LEN UCARE Conference 2023NASDAQ:PHVSPharvaris NV
15/11/202312h50GlobeNewswire Inc.Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations OfficerNASDAQ:PHVSPharvaris NV
09/11/202317h00GlobeNewswire Inc.Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific MeetingNASDAQ:PHVSPharvaris NV
02/11/202311h50GlobeNewswire Inc.Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
30/10/202311h50GlobeNewswire Inc.Pharvaris To Present at the ACAAI 2023 Annual Scientific MeetingNASDAQ:PHVSPharvaris NV
13/10/202312h50GlobeNewswire Inc.Pharvaris To Present at the APAAACI 2023 International ConferenceNASDAQ:PHVSPharvaris NV
04/10/202313h34GlobeNewswire Inc.Pharvaris To Present at the CIIC Fall 2023 ConferenceNASDAQ:PHVSPharvaris NV
19/09/202312h50GlobeNewswire Inc.Pharvaris To Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:PHVSPharvaris NV
 Showing the most relevant articles for your search:NASDAQ:PHVS

Dernières Valeurs Consultées

COIN
SWIBTC
Swinca Coin
NASDAQ
CDIO
Cardio Diagnostics
NASDAQ
TTCF
Tattooed Chef
EU
3153T
3153T
TSXV
APL
Appulse
COIN
SLSBTC
SaluS
GATE
XILUSDT
XIL
COIN
GMBIOUSD
GAMB
COIN
VEGIGBP
Veggie
EU
T621S
T621S
USOTC
RMGNF
HI Magnesita NV (PK)
HITB
SILKCHAINETH
SilkChain
UNSW
IBETHETH
Interest Bearing ETH
HUOB
GOFBTC
Golff.finance
BIT
F15593
Vontobel Financial Produ...
EU
NL00150013L5
Netherlands Nl Strip 15j...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés